ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Emera Inc.
50.08
-1.7000
-3.28%
盘后:
51.05
0.9700
+1.94%
19:30 EDT
成交量:
48.79万
成交额:
2,465.78万
市值:
153.14亿
市盈率:
22.46
高:
51.91
开:
51.91
低:
50.03
收:
51.78
52周最高:
55.49
52周最低:
45.77
股本:
3.06亿
流通股本:
3.06亿
量比:
1.75
换手率:
0.16%
股息:
2.12
股息率:
4.23%
每股收益(TTM):
2.23
每股收益(LYR):
2.47
净资产收益率:
7.56%
总资产收益率:
2.91%
市净率:
1.63
市盈率(LYR):
20.32
数据加载中...
总览
公司
新闻资讯
公告
分析师:比特币已触及长期下行趋势线及 21 个月 EMA 均线,站稳当前阻力线方能确认涨势
链捕手
·
08/21
奥麦罗斯2026财年第二季度业绩:YARTEMLEA推动运营实现收支平衡
TradingKey中文
·
08/13
Emera(EMA)上半年调整后净利润增至6.27亿加元、净收入降至6.67亿加元
金吾财讯
·
08/07
财报前瞻|Emera Inc.本季度营收预计增15.89%,机构观点偏谨慎
财报Agent
·
07/31
瑞博生物-B:核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准
智通财经
·
07/28
欧洲药品管理局(EMA):阿斯利康(AZN.US)已撤回其重磅免疫药物Imfinzi在欧盟的扩展适应症申请。
智通财经
·
07/24
Rocket Lab股价站稳200日EMA上方:获NASA合同后是否值得买入?
环球市场播报
·
06/29
恒瑞医药(600276.SH):瑞维鲁胺片上市许可申请获EMA受理
智通财经
·
06/22
新闻稿:CosmoFarm公布2026年第二季度创纪录营收超1500万美元,年化运行率超6000万美元;新增超80家药房并扩展AI自动化与设施产能
投资观察
·
06/19
从跟随者到定价者:加密市场的角色正在反转
链捕手
·
05/21
财报前瞻|Emera Inc.本季度营收预计增35.49%,盈利质量成看点
财报Agent
·
05/01
罗氏获欧洲监管机构反馈后,启动Elevidys基因疗法新研究
环球市场播报
·
04/16
港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格
智通财经
·
04/01
和誉-B(02256):FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格,用于治疗肝细胞癌
智通财经
·
03/31
交易万物,永不休市:RWA 永续合约(上)
链捕手
·
03/10
韩国与新加坡启动自贸协定升级谈判并签署核电合作备忘录
核电网
·
03/03
百奥泰:Usymro(乌司奴单抗注射液)获得英国 MHRA 上市批准
格隆汇
·
03/03
美国和伊朗的冲突让全世界的AI中断了
01Founder
·
03/03
持续创新 稳拓全球
复星医药官微
·
03/02
复宏汉霖(02696):帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见
智通财经
·
02/27
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/EMA/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.08,"timestamp":1787342400000,"preClose":51.78,"halted":0,"volume":487921,"hourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"delay":0,"changeRate":-0.03283120896098885,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"休市中","change":-1.7,"latestTime":"08-21 16:00:00 EDT","open":51.91,"high":51.91,"low":50.025,"amount":24657789.365397997,"amplitude":0.036404,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":51.78,"dividendRate":0.042108,"preHourTrading":{"tag":"盘前","latestPrice":52.07,"preClose":51.78,"latestTime":"09:00 EDT","volume":9,"amount":465.57171,"timestamp":1787317237082,"change":0.29,"changeRate":0.005601,"amplitude":0.030707},"postHourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"volumeRatio":1.7497389305446422,"impliedVol":0.0649,"impliedVolPercentile":0.1633},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.7497389305446422,"shares":305783111,"dividePrice":2.116758,"high":51.91,"amplitude":0.036404,"preClose":51.78,"low":50.025,"week52Low":45.77,"pbRate":"1.63","psRate":"2.37","week52High":55.49,"institutionHeld":0,"latestPrice":50.08,"eps":2.229761,"divideRate":0.042268,"volume":487921,"delay":0,"ttmEps":2.229761,"open":51.91,"prevYearClose":49.24,"prevWeekClose":51.51,"prevMonthClose":53.89,"prevQuarterClose":53.02,"fiveDayClose":51.51,"twentyDayClose":54.95,"sixtyDayClose":53.63,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"盘前","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"盘前","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"盘前","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-08-21","current":22.459806,"percent":0.843648,"low":16.637027,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"high":22.07626,"avg":19.793468,"sd":1.503181,"marketCap":15955602988.26},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26}],"updateTime":1787491552043},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661483293","title":"分析师:比特币已触及长期下行趋势线及 21 个月 EMA 均线,站稳当前阻力线方能确认涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=2661483293","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661483293?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 21:18","pubTimestamp":1787318280,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息,加密分析师 Rekt Capital 发布比特币技术图表分析指出,比特币正遭遇宏观下行趋势线阻力,该趋势线与 21 个月 EMA 均线拟合。Rekt Capital 认为,如果比特币在这个拟合的阻力区域受阻,那么可能在 50 个月 EMA 均线处(紫色)获得支撑。总体而言,比特币需要将这两个宏观 EMA 重新转化为新的支撑位,并突破宏观下行趋势线,以确认新一轮牛市。Rekt Capital 系资深加密技术分析师,在 X 平台拥有 56 万粉丝。 ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2284491","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTC.USD.HKCC","BTGD","YBTC","YBIT","STCE","BTF","GBTC","BKCH","BTCL","09042","GDLC","BRRR","HODL","BEGS","SBIT","NGHT","EMA","BTCZ","CRPT","HECO","SMST","BTRN","NCIQ","MSBT","BITX","BTFX","WGMI","03008","03439","ARKY","MSTU","BETH","CBTJ","BTC.USD.CC","BETE","BITW","OOQB","IBIT","BITI","BTCO","BTYB","MBTmain","BITC","BITQ","DAPP","LFGY","BITU","BTCI","MAXI","FBTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659183413","title":"奥麦罗斯2026财年第二季度业绩:YARTEMLEA推动运营实现收支平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2659183413","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659183413?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 04:18","pubTimestamp":1786565932,"startTime":"0","endTime":"0","summary":"Omeros公布2026财年第二季度产品销售净额为2850万美元,高于去年同期的零,主要得益于YARTEMLEA总收入达到3220万美元,较第一季度增长190%。按GAAP计算的净利润为1320万美元,每股基本收益为0.18美元,但其中包含1150万美元的非现金公允价值收益;非GAAP调整后净利润为180万美元。经营活动产生现金410万美元,而在7月份完成6020万美元的可转换票据回购之前,截至6月底的现金及短期投资总额为1.32亿美元。","market":"us","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/earnings/262100447-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","LU1894683264.USD","BK4007","LU0738911758.USD","LU0203347892.USD","OMER","LU0553294199.USD","LU1003077747.HKD","LU0203345920.USD","BK4588","EMA","LU0868494617.USD","NTAP","LU1894683348.USD","SG9999001440.SGD","LU0661504455.SGD","CEO","LU0949170772.SGD","BK4081","LU2637428348.USD","CMS","BK4087","BK4170","BK4585","LU2500361329.USD","LU0868494708.USD","LU0942090050.USD","BK4208","LU2346227817.USD","LU0545039389.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648031","title":"Emera(EMA)上半年调整后净利润增至6.27亿加元、净收入降至6.67亿加元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648031","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648031?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 19:34","pubTimestamp":1786102483,"startTime":"0","endTime":"0","summary":"金吾财讯 | 北美能源巨头Emera 公布2026年第二季度及上半年财务业绩。2026年二季度,Emera实现调整后净利润2.12亿加元,较上年同期的2.36亿加元有所放缓;净利润为1.05亿加元。2026年上半年,公司调整后净利润达到6.27亿加元,高于2025年上半年的6.15亿加元。期内净收入为6.67亿加元,低于去年同期的7.18亿加元。展望未来,公司预计,2026年调整后每股收益增长将超越其5%-7%的年度目标区间高位,公司重申截至2030年维持5%-7%的复合年均增长承诺。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148281703","title":"财报前瞻|Emera Inc.本季度营收预计增15.89%,机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1148281703","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148281703?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 08:42","pubTimestamp":1785458557,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年08月07日盘前发布第二季度财报,市场预期营收增长而利润承压,投资者关注盈利质量与现金流稳定性。一致预期显示,本季度Emera Inc.营收为20.29亿加元,同比增长15.89%;调整后每股收益为0.49加元,同比下降24.17%;EBIT为4.73亿加元,同比增长1.23%,上一季度未披露针对本季度的明确量化指引。上季度公司实现营收28.13亿加元,同比增长5.12%;毛利率50.20%;归属于母公司股东的净利润5.82亿加元,净利率20.69%;调整后每股收益同比增长7.00%,净利润环比增长568.97%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻|Emera Inc.本季度营收预计增15.89%,机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001188","title":"瑞博生物-B:核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001188?lang=zh_cn&edition=fundamental","pubTime":"2026-07-28 19:59","pubTimestamp":1785239982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","IBBJ","BK4081","MDTX","EMA","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653608566","title":"欧洲药品管理局(EMA):阿斯利康(AZN.US)已撤回其重磅免疫药物Imfinzi在欧盟的扩展适应症申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653608566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653608566?lang=zh_cn&edition=fundamental","pubTime":"2026-07-24 18:07","pubTimestamp":1784887647,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443465.HKD","LU2468319806.SGD","LU2089984988.USD","LU2236285917.USD","BK4007","BK4081","LU0320765992.SGD","LU1267930573.SGD","EMA","BK4588","LU2462157665.USD","LU2237443549.SGD","LU1829250122.USD","LU2456880835.USD","LU0432979614.USD","LU2237443382.USD","LU2237443622.USD","LU0058720904.USD","LU0310800379.SGD","LU2237443978.SGD","LU0109394709.USD","BK4568","LU2417539215.USD","LU0889565916.HKD","IE00B3T34201.USD","LU0708994859.HKD","LU0289739699.SGD","LU0128525929.USD","AZN","LU2237443895.HKD","LU0029864427.USD","AZNH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037238","title":"Rocket Lab股价站稳200日EMA上方:获NASA合同后是否值得买入?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037238","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647037238?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 21:09","pubTimestamp":1782738540,"startTime":"0","endTime":"0","summary":"Rocket Lab股价周一盘前交易时段上涨,此前该公司宣布将收购卫星通信运营商Iridium,交易价值约80亿美元。这一消息叠加近期获得的NASA发射合同,为股价提供了技术面支撑。 从技术走势来看,Rocket Lab股价在6月25日跌至80.69美元的低点后获得支撑,目前盘前交易于90美元附近,成功站稳200日指数移动平均线上方。 上周,NASA宣布选择Rocket Lab执行三项Electron火箭发射任务,用于PolSIR和TSIS-2科学任务,预计于2027年初启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-29/doc-inifauhn5315358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NASA","BK4081","EMA","BK0217","300785"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞医药(600276.SH):瑞维鲁胺片上市许可申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645409710?lang=zh_cn&edition=fundamental","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司收到了欧洲药品管理局(European Medicines Agency,简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请,这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT),治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU0405327148.USD","LU1655091616.SGD","BK0188","LU2543165471.USD","LU1580142542.USD","LU2148510915.USD","LU2097828631.EUR","BK4081","BK0028","LU2289578879.USD","LU2097828557.USD","LU2097828474.EUR","LU0359201885.HKD","LU2097828805.USD","LU2580892789.USD","LU1997245094.SGD","LU2328871848.SGD","EMA","LU0359202008.SGD","LU1023057109.AUD","BK0012","LU1997244956.HKD","01276","LU1146622755.USD","LU2495084118.USD","IPOS","BK1191","LU0405327494.USD","BK0060","LU1064131003.USD","LU2488822045.USD","LU1328615791.USD","LU1781817850.SGD","LU1255011170.USD","LU1997245177.USD","LU2580892862.HKD","BK0196","LU1064130708.USD","LU2097828714.EUR","LU1820825898.SGD","LU1969619763.USD","600276","BK0183","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178964593","title":"新闻稿:CosmoFarm公布2026年第二季度创纪录营收超1500万美元,年化运行率超6000万美元;新增超80家药房并扩展AI自动化与设施产能","url":"https://stock-news.laohu8.com/highlight/detail?id=1178964593","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178964593?lang=zh_cn&edition=fundamental","pubTime":"2026-06-19 03:35","pubTimestamp":1781811307,"startTime":"0","endTime":"0","summary":"Cosmos Health Inc.今日宣布,其全资子公司CosmoFarm S.A.在2026年第二季度实现了超过1500万美元的创纪录营收,这相当于超过6000万美元的年化运行率。Cosmos Health是一家业务多元化、垂直整合的全球医疗健康集团。在此期间,CosmoFarm在其分销网络中新增了超过80家药房,延续了强劲的客户增长势头,这使其已成为大雅典地区领先的医药批发商之一。为了支持这一加速增长,Cosmos Health正在增加CosmoFarm的资本支出,投资于新的机器人自动化与人工智能系统,以优化采购、库存管理和订单履行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","AGIX","ARTY","AIPO","BK4175","BK4022","BK4232","EMA","BK4081","CHAT","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637806473","title":"从跟随者到定价者:加密市场的角色正在反转","url":"https://stock-news.laohu8.com/highlight/detail?id=2637806473","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637806473?lang=zh_cn&edition=fundamental","pubTime":"2026-05-21 12:09","pubTimestamp":1779336566,"startTime":"0","endTime":"0","summary":" 加密平台在 CBRS 上市前成功实现了精准的先期定价,这表明 Crypto 正凭借创新机制,逐步从传统金融的跟随者转变为全球资产的新定价中枢。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2266266","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","CBRS","FAZ","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185761853","title":"财报前瞻|Emera Inc.本季度营收预计增35.49%,盈利质量成看点","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185761853?lang=zh_cn&edition=fundamental","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩,市场关注营收增速与成本控制的落地情况。根据一致预期,本季度Emera Inc.营收预计为30.09亿加元,同比增长35.49%;调整后每股收益预计为1.15加元,同比增长15.55%;息税前利润预计为7.02亿加元,同比增长7.05%;当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Emera Inc.本季度营收预计增35.49%,盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"罗氏获欧洲监管机构反馈后,启动Elevidys基因疗法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627213629?lang=zh_cn&edition=fundamental","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布,在收到欧洲药品监管机构的反馈后,将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症,由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前,因两例患者死亡事件与该疗法相关而引发审查,这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩,其中包括美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624593383?lang=zh_cn&edition=fundamental","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上,和誉宣布,其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格,用于治疗肝细胞癌。目前,依帕戈替尼正在全球多地开展临床研究,此次获EMA授予ODD,将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外,依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定,以及中国国家药品监督管理局授予的突破性疗法认定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","VXUS","IE00B543WZ88.USD","BK4081","LU2778985437.USD","EMA","IE00B5MMRT66.SGD","LU2476274308.USD","BK1161","IE00BPRC5H50.USD","LU2488822045.USD","LU2476274720.SGD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和誉-B(02256):FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格,用于治疗肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623581546?lang=zh_cn&edition=fundamental","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B 发布公告,公司附属公司上海和誉生物医药科技有限公司宣布,其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格,用于治疗肝细胞癌。目前,依帕戈替尼正在全球多地开展临床研究,此次获EMA授予ODD,将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","LU2488822045.USD","BK1161","02256","BK4081","LU2778985437.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","EMA","LU2476274308.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618601928","title":"交易万物,永不休市:RWA 永续合约(上)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601928","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618601928?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 09:24","pubTimestamp":1773105857,"startTime":"0","endTime":"0","summary":" RWA 永续合约正试图用透明的链上“线性杠杆”,颠覆传统金融中成本高昂的末日期权(0DTE)与充满黑箱的差价合约(CFD)市场。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2250726","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNX.USD.CC","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616376696","title":"韩国与新加坡启动自贸协定升级谈判并签署核电合作备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2616376696","media":"核电网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616376696?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 18:22","pubTimestamp":1772533330,"startTime":"0","endTime":"0","summary":"近日,韩国总统李在明对新加坡进行了国事访问,两国就升级韩-兴自由贸易协定及核电合作达成重要共识。韩国产业通商资源部长官与新加坡贸工部代表于3月2日共同签署了《关于启动韩新自贸协定升级谈判的联合宣言》。与此同时,韩国水电与核电公司和新加坡能源市场厅也签署了关于小型模块化反应堆合作的谅解备忘录,这标志着韩国核电企业首次与新加坡政府机构在核电领域建立正式合作关系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303202141a69d90f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4081","BK4606","NLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616698376","title":"百奥泰:Usymro(乌司奴单抗注射液)获得英国 MHRA 上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616698376","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616698376?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 16:33","pubTimestamp":1772526786,"startTime":"0","endTime":"0","summary":"格隆汇3月3日丨百奥泰公布,公司于近日收到了英国药品和健康产品管理局签发的关于Usymro上市批准通知。截至本公告披露日,BAT2206已获得美国FDA、欧洲 EMA 和英国 MHRA 批准上市,美国注册商品名称为STARJEMZA,欧洲注册商品名称为 Usymro;已向中国 NMPA 递交上市许可申请,目前正在评审中。Usymro获得英国 MHRA 上市批准后可在英国进行销售,公司海外销售产品品类得到进一步扩充,将进一步提升公司产品的国际影响力,有望对公司长期经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163601a445ce72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616836227","title":"美国和伊朗的冲突让全世界的AI中断了","url":"https://stock-news.laohu8.com/highlight/detail?id=2616836227","media":"01Founder","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616836227?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 06:51","pubTimestamp":1772491887,"startTime":"0","endTime":"0","summary":"根据路透社和当地媒体随后拼凑出的碎片信息:不明物体击中了数据中心的配套电力设施。为了防止火势蔓延引发更大的次生灾害,自动消防系统接管了现场,电力供应被强制切断。而且受影响的远不止 AI。在过去的战争逻辑中,轰炸的目标是切断能源或交通。这就是现代世界的超距作用。一家估值千亿的 AI 公司,其命脉竟然维系于沙漠中一座机房的安保状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8rBQys8bxg4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4543","GTM","BK4587","BK4023","BK4077","AIYY","APAC","BK4585","UAE","BK4551","BK4528","BK4081","BK4588","EMA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2616533009","title":"持续创新 稳拓全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533009","media":"复星医药官微","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616533009?lang=zh_cn&edition=fundamental","pubTime":"2026-03-02 21:49","pubTimestamp":1772459340,"startTime":"0","endTime":"0","summary":"创新抗PD-1单抗汉斯状 迈向更广阔国际市场,复星医药子公司复宏汉霖再拓全球布局03汉利康上市七周年 | 以实证行致远,引领一个更可及的治疗时代七年,足以让一粒创新的种子长成惠及数十万患者的生命之树;七年,也见证了中国首个生物类似药从“破冰者”到“领航者”的征程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-02/doc-inhprfsh8091981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1191","BK1593","02196","BK4087","CHMP","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614085473","title":"复宏汉霖(02696):帕妥珠单抗生物类似药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085473?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 22:27","pubTimestamp":1772202451,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖 发布公告,近日,HLX11获EMA人用医药产品委员会积极审评意见,推荐批准HLX11的上市许可申请。倘若获得EC批准,HLX11的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。HLX11是本公司自主研发的帕妥珠单抗生物类似药。2024年12月,HLX11的上市注册申请获国家药品监督管理局受理。2025年3月,HLX11的上市许可申请获欧洲药品管理局受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","09939","BK4087","CHMP","HK0000306701.USD","EMA","HK0000165453.HKD","HK0000320223.HKD","HK0000306685.HKD","02696","159938","BK1515","BK4081","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}